Second-generation antipsychotics (SGAs) are better for psychotic disorders, and they can induce weight gain and other serious metabolic adverse effects which can lead to non-adherence and medical comorbidities. Iloperidone and asenapine, the newer SGAs with favorable short-term side effect profile. Aims and Objective: The aim of this study was to compare the weight gain propensity associated with new SGAs drugs-asenapine and iloperidone. . 60 patients who met the criteria for acute psychosis

more »

... schizophrenia according to ICD 10 were recruited. Atypical antipsychotics, asenapine (5-20 mg), and iloperidone (8-24 mg) were administered, and their weight was measured using the digital weighing scale on day 0 (baseline), week 1, week 3, and week 6. Results: Out of 60 recruited subjects, 51 (85%) completed all four visits of the study, 41.67% with asenapine, 43.3% with iloperidone. Mean weight gain was 2.18 ± 1.84 kg with iloperidone and 1.63 ± 1.28 kg with asenapine, but it was not statistically significant between the groups. Weight gain was dose dependent; 3.56 kg mean weight gain with 15-20 mg of asenapine and 3.36 kg with 18-24 mg iloperidone-treated patients which was statistically significant. Conclusion: Mild to moderate weight gain was seen in both asenapine and iloperidone and it was dose dependent. Iloperidone showed more weight gain than asenapine.